The Development of Modern Methodologies
the first half of the 20th Century, researchers began to conduct clinical studies in the hopes of developing a vaccine for Leishmaniasis. As early as the 1930s, scientists in South America and
developed methods for the preparation of a Leishmaniasis vaccine comprised of multiple strains of dead Leishmania sp. Promastigotes. These early vaccines yielded a number of positive results. The early studies even suggested that a sufficient immuno-reaction to the developed vaccine would provide a substantial degree of protection against infection with minimal side effects.
Many contemorporary clinical studies have attempted to expand upon the initial success of these earlier studies, however, because of a host of factors discussed in the RESEARCH section, progress has been hindered.
Looking to the Future...
Scientific innovation, technology, and advances in modes of production have
effected changes in the ways in which scientists now think about developing a Leishmaniasis vaccine. Current vaccine innovation efforts have put a focus on novel antigens and adjuvants such as Alum, BCG (Bacillus Calmette-Guérin) and MPL (Monophosphoryl Lipid A), live-attenuated vaccines, recombinant antigens, plasmid DNA, bacteria expressing leishmanial antigens, Leishmania Activiated C-Kinase (LACK) and dendritic cells.
PHOTO CAPTIONS:eishmaniasis vaccine production - a laboratory technician checking the stainless steel vats containing leishmaniasis vaccine" - WHO/TDR/Crump
(R) "Bottles of leishmaniasis vaccine produced in the Razi Institute, Teheran (IRAN) " - WHO/TDR/Crump